--- title: 'Study Start Up Lead Contractor at Entrada Therapeutics' canonical: 'https://feeny.ai/job/study-start-up-lead-contractor-entrada-therapeutics-boston-1jawrme3qtyp' type: 'job' last_seen: '2026-09-06' --- # Study Start Up Lead Contractor at Entrada Therapeutics - **Company:** Entrada Therapeutics - **Location:** Boston, MA - **Posted:** 2026-08-19 - **Last confirmed live:** 2026-09-06 - **Apply:** https://job-boards.greenhouse.io/entradatherapeutics/jobs/5216635007 ## Job description The Organization What's happening at Entrada Therapeutics? Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary and versatile approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered with Vertex Pharmaceuticals to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1 (DM1). 2026 represents a catalyst-rich period for Entrada. We expect multiple clinical data readouts as we advance several DMD programs across the U.K., EU, and U.S. By year-end 2026, we anticipate four clinical-stage programs in our DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51). These programs are complemented by the ongoing clinical progress of our DM1 collaboration with Vertex (VX-670). We are a tight-knit team of experts and leaders in both therapeutic development and rare diseases and are excited to grow and attract colleagues who are ready to join a high-energy, dedicated team that likes to get things done and dramatically improve the lives of patients and their families. The Perfect Addition to Our Team You are excited about the opportunity to spearhead clinical trial start up activities. You are well organized and like to share best practices in clinical operations and study start up. You enjoy a fast-paced environment and juggling competing priorities and are willing to jump in and help wherever it is needed. You follow up and follow through, efficiently connecting problems with solutions. You work successfully in a team environment and have strong interpersonal skills, in order to effectively build working relationships inside and outside of the company. The Opportunity This individual will partner with study leads on varying operational initiatives across on-going and new clinical studies for study start up and enrollment. This role will support the overall planning and management of clinical trials, including CRO and vendor oversight, to achieve project milestones and clinical study timelines in alignment with company goals and in compliance with local, ICH, GCP, and company policies and procedures. ## Responsibilities - Lead and/or support Sr. CTMs/CTMs with study start up and maintenance activities, including regulatory submissions, country and site selection, site budget management, site activation, ICF review, etc. - Collaborate with Sr. CTM/CTMs on developing study specific strategic start up or protocol amendment implementation plans. - Drive start-up activities including timely site selection and activation, EC submissions and query responses, document collection, and protocol amendment activities. - Reviewing country-level ICFs and related site or patient facing materials and routing for approval by required functional areas. - Review and approve site activation packages and regulatory documentation, ensuring complete and accurate information tracked in the appropriate databases. - Proactively identify and support resolution/escalation of issues impacting start up or trial execution. - Collaborate and communicate with the cross-functional trial team, including collaborating with internal team members and external vendors on related study start up activities. - Ensure that all assigned start up activities are on track and support study deliverables. - Partner with relevant stakeholders to develop and implement appropriate study-specific training and kick-off meetings to all relevant study-related personnel (internal, CRO, Site staff, and other relevant 3rd parties) The Necessities At Entrada, our passion for science, our devotion to patients and our values drives our behavior: - Humanity - We genuinely care about patients and about one another. - Tenacity - We are relentless and persistent in the pursuit of developing therapies for patients. - Creativity - We are creative problem solvers. - Collaboration - We are more than the sum of our parts. - Curiosity - We have a growth mindset and push conventional thought and theory. To thrive on our team, you will need to come with: - BA/BS degree with 8 + years of combined experience supporting and independently managing clinical trial activities globally. - Strong knowledge of ICH/GCP and regulatory requirements. - Strong experience in the drug development process, including trial design, trial planning and management, and CRO and vendor oversight. - Excellent verbal and written communication skills. - Proven ability to work effectively across functions. - Ability to travel approximately 10% of the time, as determined by the needs of the business. This is a part-time, long-term contract position estimated to be ~20-30 hours per week. The role is a US based remote position, with preference given to local New England based candidates. This role may require ad-hoc travel to the Entrada Therapeutics Headquarters located in Boston, MA. #LI-JF1 #LI-Remote ## Equal Opportunity Employer Entrada Therapeutics is an equal opportunity employer. Qualified candidates will receive consideration for employment without regard to race, color, religion, national origin, gender, sexual orientation, gender identity or expression, age, mental or physical disability, and genetic information, marital status, citizenship status, military status, protected veteran status or any other category protected by law. Third Party Staffing Agencies Entrada does not accept unsolicited resumes from any source other than directly from candidates. For the protection of all parties involved in the recruiting process, resumes will only be accepted from recruiters/agencies if a signed agreement is in place at the inception of the recruiting effort and authorized for a specified position. Unsolicited resumes sent to Entrada from recruiters/agencies do not constitute any type of relationship between the recruiter/agency and Entrada and do not obligate Entrada to pay fees if we hire from those resumes. Privacy Statement Entrada Therapeutics, Inc. (the “Entrada,” “we,” “us,” or “our”) respects your privacy and we want you to be familiar with how we collect, use, share, or otherwise process, your Personal Information. Please reference our privacy statement [here](https://www.entradatx.com/privacy-notice)to understand how and when your data is being used. ## About Entrada Therapeutics ## Company Overview - **One-liner**: Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary Endosomal Escape Vehicle (EEV™) platform to deliver genetic medicines to previously inaccessible intracellular targets for devastating diseases. - **Entity Type**: Public (NASDAQ: TRDA) - **Headquarters**: Boston, Massachusetts, United States - **Founded**: 2016 - **Founders**: Not publicly listed on the company website; leadership team includes CEO Dipal Doshi, CFO Kory Wentworth, and President of R&D Natarajan Sethuraman. ## Core Business - **Primary industry**: Biotechnology – genetic medicines and intracellular therapeutics - **Target customers**: B2B (partnerships with pharma like Vertex) and ultimately patients with rare neuromuscular and retinal diseases - **Mission**: To treat devastating diseases with intracellular therapeutics, focusing on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and inherited retinal diseases. ## Products & Services - **EEV™ Platform**: A proprietary, modular delivery technology designed to enable efficient intracellular delivery of oligonucleotides, proteins, and other therapeutics into a wide range of tissues (muscle, retina, etc.) with an improved therapeutic index. - **Clinical-stage programs (DMD franchise)**: - ENTR-601-44, ENTR-601-45, ENTR-601-50, ENTR-601-51 – exon-skipping oligonucleotides for DMD patients amenable to skipping exons 44, 45, 50, and 51. Multiple programs have advanced into clinical trials in the U.K., EU, and U.S. - **Collaboration program**: - VX-670 (with Vertex Pharmaceuticals) – a clinical-stage therapy for myotonic dystrophy type 1 (DM1). - **Pipeline (preclinical)**: Additional programs in neuromuscular and inherited retinal diseases. ## Market Standing - **Valuation/Market Cap**: $711.3 million (as of mid-2026, per LinkedIn data) - **Key Metric (Revenue)**: $25.4 million annual revenue (2025/2026 estimate from LinkedIn) - **Notable Investors/Partners**: Vertex Pharmaceuticals (strategic collaboration); publicly traded with institutional investors - **Growth Signals**: - IPO in 2021 - 2026 described as a “catalyst-rich period” with multiple clinical data readouts expected - Four clinical-stage DMD programs by year-end 2026 - Positive safety data from ELEVATE-45-201 study leading to dose escalation (10 mg/kg cohort) - Headcount of 168 employees (down ~6% YoY, indicating possible restructuring or natural attrition) ## Competitive Advantages - **Proprietary EEV™ Platform**: Enables intracellular delivery of large molecules that cannot cross cell membranes, unlocking “undruggable” targets – a significant differentiator in the genetic medicine space. - **Modular and versatile**: Platform can be applied across multiple therapeutic areas (neuromuscular, retinal, metabolic) and modalities (oligonucleotides, proteins, gene editors). - **Deep DMD franchise**: Entrada is building one of the broadest exon-skipping pipelines for DMD, targeting multiple patient subpopulations. - **Strategic partnership with Vertex**: Validates the platform and provides co-development resources for DM1. ## Strategic Focus - **Near-term**: Deliver clinical proof-of-concept for DMD programs (data readouts through 2026) and advance VX-670 in DM1. - **Pipeline expansion**: Continue to broaden the EEV platform into new tissues and disease areas, including inherited retinal diseases and metabolic disorders. - **Commercial readiness**: Build internal capabilities for potential future product launches while maintaining a lean, high-impact R&D organization. ## Why Work Here - **Culture**: Described as a “tight-knit team of experts and leaders” with a mission-driven, collaborative, and high-energy environment. Values include humanity, curiosity, and a growth mindset. - **Diversity & Inclusion**: As of October 2025, 58% of employees identify as women, 45% as Asian, Hispanic, Latino, African American, or two or more races; 64% of senior leadership and board are women and minorities. Employee Resource Groups (ERGs) are active. - **Work Model**: Flexible working – role-dependent remote options; employees choose where they work best. Commuter benefits (up to $325/month) for those who come to the Boston Seaport office. - **Benefits**: Comprehensive – fully subsidized lunches/snacks, $500 wellbeing stipend, gender-inclusive parental leave, education reimbursement, mental health and financial coaching, HSA contributions, and milestone celebrations. - **Perks**: In-office fuel (free food/drinks), regular team events, and a strong emphasis on work-life balance. - **Open Roles**: Positions include clinical trial management, regulatory affairs, drug substance development, IT support, and more – posted on Greenhouse. ## Sources 1. [entradatx.com](https://www.entradatx.com/) – Company overview, platform, pipeline, mission 2. [entradatx.com/about](https://www.entradatx.com/about) – Leadership team, company history 3. [entradatx.com/careers](https://www.entradatx.com/careers) – Culture, benefits, diversity stats, open positions 4. [linkedin.com/company/entradatx](https://www.linkedin.com/company/entradatx) – Headcount, revenue, market cap, industry classification 5. [job-boards.greenhouse.io/entradatherapeutics](http://job-boards.greenhouse.io/entradatherapeutics) – Current job listings ## Other roles at Entrada Therapeutics - [Associate Director, Drug Product Development & Manufacturing](https://feeny.ai/job/associate-director-drug-product-development-manufacturing-entrada-therapeutics-p593cry5gk61) — Boston, MA - [Associate Director, Analytical Development & Quality Control](https://feeny.ai/job/associate-director-analytical-development-quality-control-entrada-therapeutics-z1f7fbqpchmp) — Boston, MA - [Director, Regulatory Writing](https://feeny.ai/job/director-regulatory-writing-entrada-therapeutics-boston-ab86t5fmrhhn) — Boston, MA - [Biostatistician Lead Consultant](https://feeny.ai/job/biostatistician-lead-consultant-entrada-therapeutics-boston-xm6k30zmvmd1) — Boston, MA - [Director, Clinical Data Management](https://feeny.ai/job/director-clinical-data-management-entrada-therapeutics-boston-8qj8p2s34wxj) — Boston, MA - [Associate Manager, Human Resources](https://feeny.ai/job/associate-manager-human-resources-entrada-therapeutics-boston-cdb994v6z81c) — Boston, MA - [Principal Biostatistician](https://feeny.ai/job/principal-biostatistician-entrada-therapeutics-boston-2t2p3g7s40q5) — Boston, MA - [Senior Clinical Trial Manager](https://feeny.ai/job/senior-clinical-trial-manager-entrada-therapeutics-boston-p2v2qj071nzt) — Boston, MA